Abstract 365P
Background
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Malaysia and the incidence rate is high in the state of Sabah. Patients in Sabah are known to have limitations to access the healthcare services in the state. The purpose of this study is to examine the survival results, failure patterns, and compliance rate of patients with nasopharyngeal cancer who received radical radiotherapy with or without chemotherapy in Sabah.
Methods
A retrospective analysis was performed on patients diagnosed with stage I-IVA (AJCC staging 8th edition) NPC and treated with radiotherapy between the years of 2017-2019 in Sabah Women and Children's Hospital. The Kaplan-Meier method was used for survival analysis and differences in survival according to AJCC stage was compared using the log-rank test.
Results
A total of 140 patients were treated during this period. Most of them presented late at diagnosis, stage III (39%) and stage IVA (40%). Majority of them were treated with IMRT technique (85%). The compliance rate to radiotherapy was 96%. The 3-year overall survival (OS), disease-free-survival (DFS), local-failure-free survival (LFFS), regional-failure-free survival (RFFS), distant-failure-free survival (DFFS), of NPC patients in this study are 70%, 61%, 83%, 84%, and 67% respectively. The LFFS was significantly different between T stages (P value = 0.003) and T4 stage had the lowest rate of 3-year LFFS (65%). The RFFS was significantly different between N stages (P value = 0.013) and the 3-year RFFS probability for N3 stage was markedly lower than the rest (63%). The DFFS was significantly different between N stages (P-value < 0.001) and the 3-year DFFS probability decreased as N stage increased.
Conclusions
The 3-year OS and 3-year DFS rates in our study are comparable to those in peninsular Malaysia. The LFFS for T1-T3 stages is high. However, LFFS is low in T4 disease and DFFS is significantly low in N3 disease. Hence prospective studies are needed to determine if this group of patients may benefit from an intensified systemic treatment. Despite facing many challenges to access healthcare in Sabah, NPC patients in the state have a remarkably high compliance rate to radiotherapy treatment.
Clinical trial identification
NMRR ID-23-00055-E3N; RSCH ID-22-02599-GSk.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract